Biotechnology

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...

2024-08-20 16:32 2968

Allozymes and Adisseo Partner on Next-Gen Animal Feed Production Using Rapid Microfluidics Technology

SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Allozymes, a leading innovator in enzyme discovery and engineering, today announces a strategic partnership with Adisseo, one of the world's leading animal nutrition companies, to develop groundbreaking bioprocesses for animal feed ingredient production. T...

2024-08-19 15:57 3561

Ainex Unveils Advanced Endoscopy AI System at GIHEP & Singapore Hepatology Conference 2024

SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Ainex Corporation, a leading innovator in medical technology, has unveiled its advanced Endoscopy AI system, ENAD (Endoscopy as AI-powered Device), at the Combined GIHEP & Singapore Hepatology Conference 2024. This prestigious event, bringing together glob...

2024-08-19 08:01 3429

Alphamab Oncology Reports 2024 Interim Results and Business Highlights

SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...

2024-08-16 11:18 4398

Cresilon Receives FDA Clearance for TRAUMAGEL

Hemostatic gel designed to control moderate to severe bleeding in seconds and save lives NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced it has received U.S. Food and Dru...

2024-08-15 20:45 2900

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...

2024-08-15 13:43 2476

NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations

* The collaboration focuses on offering guidance, mentorship, and access to expertise to the start-ups housed within NSG Biolabs SINGAPORE, Aug. 15, 2024 /PRNewswire/ --NSG BioLabs , Singapore's largest provider of biotech co-working laboratory and office space, and the Lif...

2024-08-15 10:00 4367

Australian biotech incubator Proto Axiom announces $20M Series B first close

$20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at$90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a$20 million first close of its targeted$30 million Series B, to bolster Australia's...

2024-08-13 10:21 4347

Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE

ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Ce...

2024-08-13 09:52 4140

Pantai Hospital Kuala Lumpur Introduces Outpatient Parenteral Antimicrobial Therapy (OPAT) for Improved Patient Care

KUALA LUMPUR, Malaysia, Aug. 12, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) has officially introduced its Outpatient Parenteral Antimicrobial Therapy (OPAT) service, offering an innovative treatment option that enhances patient care.

2024-08-13 08:53 2963

German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation

BAODING, China, Aug. 12, 2024 /PRNewswire/ -- A landmark German delegation, led by world-renowned stem cell expert Prof. Dato' Sri Dr.Mike Chan, concluded a three-day visit to Baoding,China, marking a significant step in international health cooperation. The visit, fromJuly 11-13, reciprocated an...

2024-08-12 12:08 3437

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell  therapy IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of...

2024-08-07 23:37 4178

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

* Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] * Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mo...

2024-08-07 09:00 3260

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 3020

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 2810

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2024-08-06 18:47 3356

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept h...

2024-08-06 17:00 3396

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO ® in other ASEAN markets including Thailand and Indonesia with app...

2024-08-06 08:00 3106

Everest Medicines to Announce 2024 Interim Results on August 28, 2024

SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...

2024-08-06 07:30 4507

Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced f...

2024-08-05 21:00 2731
1 ... 57585960616263 ... 185